Altimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give Altimmune an average rating of "Moderate Buy" from 10 analysts (7 buys, 1 hold, 2 sells) with an average 12‑month price target of $18.00.
• The stock trades near $2.85 (12‑month range $2.80–$7.73) with a $370M market cap and reported negative EPS (‑$0.27 vs. ‑$0.25 expected), highlighting weak fundamentals despite the higher analyst targets.
• Insider and institutional activity is notable: the CEO purchased 20,000 shares at $3.54 (insiders own 1.6%), while institutional investors hold about 78.05% of the shares.

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) has been given an average rating of "Moderate Buy" by the ten analysts that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $18.00.

ALT has been the topic of several recent analyst reports. Truist Financial initiated coverage on shares of Altimmune in a research report on Wednesday, March 18th. They set a "buy" rating and a $12.00 target price on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Altimmune in a research report on Friday, March 27th. HC Wainwright upped their target price on shares of Altimmune from $12.00 to $25.00 and gave the stock a "buy" rating in a research report on Monday, March 16th. William Blair restated a "market perform" rating on shares of Altimmune in a research report on Thursday, March 5th. Finally, B. Riley Financial lowered their target price on shares of Altimmune from $18.00 to $13.00 and set a "buy" rating on the stock in a research report on Friday, March 6th.

Altimmune Trading Down 0.2%

Shares of ALT opened at $2.85 on Monday. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.15. The firm's 50-day moving average is $3.64 and its two-hundred day moving average is $4.19. Altimmune has a twelve month low of $2.80 and a twelve month high of $7.73. The firm has a market capitalization of $370.13 million, a P/E ratio of -2.82 and a beta of 0.34.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its earnings results on Thursday, March 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.02). Altimmune had a negative return on equity of 49.35% and a negative net margin of 214,860.98%.The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.00 million. On average, research analysts predict that Altimmune will post -1 earnings per share for the current fiscal year.

Insider Activity at Altimmune

In other Altimmune news, CEO Jerome Benedict Durso purchased 20,000 shares of the stock in a transaction dated Friday, March 6th. The shares were acquired at an average cost of $3.54 per share, for a total transaction of $70,800.00. Following the completion of the transaction, the chief executive officer directly owned 32,500 shares of the company's stock, valued at $115,050. This trade represents a 160.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 1.60% of the stock is owned by corporate insiders.

Institutional Trading of Altimmune

Large investors have recently modified their holdings of the business. Arax Advisory Partners grew its position in shares of Altimmune by 99.7% in the fourth quarter. Arax Advisory Partners now owns 8,165 shares of the company's stock valued at $29,000 after purchasing an additional 4,076 shares during the last quarter. SBI Securities Co. Ltd. grew its position in shares of Altimmune by 27.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company's stock valued at $32,000 after purchasing an additional 1,928 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in shares of Altimmune in the fourth quarter valued at approximately $36,000. Victory Capital Management Inc. acquired a new stake in shares of Altimmune in the third quarter valued at approximately $38,000. Finally, CreativeOne Wealth LLC acquired a new stake in shares of Altimmune in the fourth quarter valued at approximately $38,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune's approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.